Literature DB >> 33264073

Lymphocyte Subset Alteration and Monocyte CD4 Expression Reduction in Patients with Severe COVID-19.

Sumeyye Kazancioglu1, Fatma Meric Yilmaz2,3, Aliye Bastug4, Arzu Sakallı2, Bahadır Orkun Ozbay1, Cansu Buyuktarakci1, Hurrem Bodur4, Gulsen Yilmaz2,3.   

Abstract

The spectrum of coronavirus disease 2019 (COVID-19) severity, related to cellular immune functions, has not been fully clarified yet. Therefore, this study aimed to investigate the alteration of peripheral blood cells in patients with COVID-19. The flow cytometric characterization of immune cell subset was performed on 69 COVID-19 patients and 21 healthy controls. These data were evaluated based on the disease severity. A total of 69 patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were classified as asymptomatic infection (n = 14), nonsevere (n = 39), and severe (n = 16) groups. Decreased lymphocytes and increased CD14 + 4- monocytes are found in patients with severe COVID-19. Decreased CD4 expression level was observed in the monocytes of patients with severe COVID-19. The total lymphocytes, B and T lymphocytes, CD4+ cells and CD8+ cells, and natural killer (NK) and natural killer T (NKT) cells were found to be decreased in patients with severe COVID-19. The CD4+/CD8+ ratio was not significantly different between patients with COVID-19 and healthy controls. The percentage of activated T cells (CD3+HLA-DR+) and B cells (CD19+CD38+) was lower in patients with severe COVID-19. Age and CD4- monocytes were independent predictors of disease severity. The SARS-CoV-2 infection may affect lymphocyte subsets, resulting in decreased T and B cells, monocytes, and NK and NKT cells. Decreased CD4 expression level by monocytes was significantly correlated with disease severity. Further studies on the host immune response to SARS-CoV-2 infection are necessary to predict the disease severity and protect against the virus.

Entities:  

Keywords:  CD4; COVID-19; SARS-CoV-2; coronavirus; cytometry; lymphocyte; monocyte

Mesh:

Substances:

Year:  2020        PMID: 33264073     DOI: 10.1089/vim.2020.0166

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  9 in total

Review 1.  COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response.

Authors:  Ivan Gur; Amir Giladi; Yonathan Nachum Isenberg; Ami Neuberger; Anat Stern
Journal:  Acta Haematol       Date:  2022-03-02       Impact factor: 3.068

2.  Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels.

Authors:  Anthony Dobi; Arthur Dubernet; Mahary Lalarizo Rakoto; Anne-Laure Sandenon Seteyen; Damien Vagner; Grégorie Lebeau; Loïc Raffray; Philippe Gasque
Journal:  Immunol Res       Date:  2022-06-09       Impact factor: 4.505

3.  The effect of cell isolation methods on the human transcriptome profiling and microbial transcripts of peripheral blood.

Authors:  Yanru Xing; Xi Yang; Haixiao Chen; Sujun Zhu; Jinjin Xu; Yuan Chen; Juan Zeng; Fang Chen; Mark Richard Johnson; Hui Jiang; Wen-Jing Wang
Journal:  Mol Biol Rep       Date:  2021-04-30       Impact factor: 2.316

4.  Nitrogen dioxide pollution increases vulnerability to COVID-19 through altered immune function.

Authors:  Agostino Di Ciaula; Leonilde Bonfrate; Piero Portincasa; C Appice; A Belfiore; M Binetti; G Cafagna; G Campanale; A Carrieri; G Cascella; S Cataldi; A Cezza; M Ciannarella; L Cicala; F D'Alitto; A Dell'Acqua; L Dell'Anna; M Diaferia; G Erroi; F Fiermonte; I Galerati; M Giove; L Grimaldi; C Mallardi; E Mastrandrea; G D Mazelli; G Mersini; G Messina; M Messina; A Montesano; A Noto; M E Novielli; M Noviello; M V Palma; V O Palmieri; F Passerini; F Perez; C Piro; F Prigigallo; S Pugliese; O Rossi; C Stasi; R Stranieri; G Vitariello
Journal:  Environ Sci Pollut Res Int       Date:  2022-02-08       Impact factor: 5.190

5.  Increased Expression of Tim-3 Is Associated With Depletion of NKT Cells In SARS-CoV-2 Infection.

Authors:  Jingzhi Yang; Teding Chang; Liangsheng Tang; Hai Deng; Deng Chen; Jialiu Luo; Han Wu; TingXuan Tang; Cong Zhang; Zhenwen Li; Liming Dong; Xiang-Ping Yang; Zhao-Hui Tang
Journal:  Front Immunol       Date:  2022-02-16       Impact factor: 7.561

Review 6.  Pathological effects of SARS-CoV-2 on hematological and immunological cells: Alterations in count, morphology, and function.

Authors:  Ehsan Ahmadi; Zahra Bagherpour; Elmira Zarei; Azadeh Omidkhoda
Journal:  Pathol Res Pract       Date:  2022-01-29       Impact factor: 3.250

7.  Immune Cells Profiles In The Peripheral Blood Of Patients With Moderate To Severe COVID-19 And Healthy Subjects With and Without Vaccination With The Pfizer-BioNTech mRNA Vaccine.

Authors:  Raja'a Al-Attiyah; Hussain A Safar; Lotfy Botras; Marina Botras; Fatma Al-Kandari; Wassim Chehadeh; Abu Salim Mustafa
Journal:  Front Immunol       Date:  2022-07-11       Impact factor: 8.786

8.  Lymphocyte Subsets in Mild COVID-19 Pediatric Patients.

Authors:  Mustafa Argun; Doğan Bahadır İnan; Hatice Tuna Hörmet Öz; Mustafa Orhan Duyar; Göksu Başargan; Ferhan Elmalı; İlhami Çelik
Journal:  Turk Arch Pediatr       Date:  2022-03

9.  Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia.

Authors:  David C Klonoff; Jordan Messler; Timothy Valk; Ram Jagannathan; Francisco J Pasquel; Guillermo E Umpierrez
Journal:  J Diabetes Sci Technol       Date:  2021-06-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.